Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 183

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Open access
Wagner, Andrew J., Ravi, Vinod, Riedel, Richard F., Ganjoo, Kristen, Van Tine, Brian A., Chugh, Rashmi, Cranmer, Lee, Gordon, Erlinda M., Hornick, Jason L., Du, Heng, Grigorian, Berta, Schmid, Anita N., Hou, Shihe, Harris, Katherine, Kwiatkowski, David J., Desai, Neil P., Dickson, Mark A. · 2021 · Journal of Clinical Oncology

Abstract

PURPOSE: Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease, investigating the safety and efficacy of the mammalian target of rapamycin inhibitor nab-sirolimus (AMPECT, NCT02494570 ). PATIENTS AND METHODS: Patients with malignant PEComa were treated with nab-sirolimus 100 mg/m 2 intravenously once weekly for 2 weeks in 3-week cycles. The primary end point was objective response rate evaluated by independent radiology review. Key secondary end points included duration of response, progression-free survival, and safety. A key exploratory end point was tumor biomarker analysis. RESULTS: Thirty-four patients were treated (safety evaluable), and 31 were evaluable for efficacy. The overall response rate was 39% (12 of 31; 95% CI, 22 to 58) with one complete and 11 partial responses, 52% (16 of 31) of patients had stable disease, and 10% (3 of 31) had progressive disease. Responses were of rapid onset (67% by week 6) and durable. Median duration of response was not reached after a median follow-up for response of 2.5 years, with 7 of 12 responders with treatment ongoing (range, 5.6-47.2+ months). Twenty-five of 31 patients had tumor mutation profiling: 8 of 9 (89%) patients with a TSC2 mutation achieved a confirmed response versus 2 of 16 (13%) without TSC2 mutation ( P < .001). The median progression-free survival was 10.6 months (95% CI, 5.5 months to not reached), and the median overall survival was 40.8 months (95% CI, 22.2 months to not reached). Most treatment-related adverse events were grade 1 or 2 and were manageable for long-term treatment. No grade ≥ 4 treatment-related events occurred. CONCLUSION: nab-Sirolimus is active in patients with malignant PEComa. The response rate, durability of response, disease control rate, and safety profile support that nab-sirolimus represents an important new treatment option for this disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.21.01728

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 183

Metadata

Authors
Wagner, A. J., Ravi, V., Riedel, R. F., Ganjoo, K., Van Tine, B. A., Chugh, R., Cranmer, L., Gordon, E. M., Hornick, J. L., Du, H., Grigorian, B., Schmid, A. N., Hou, S., Harris, K., Kwiatkowski, D. J., Desai, N. P., & Dickson, M. A.
Venue
Journal of Clinical Oncology
Published
2021-11-20
Volume
39
Issue
33
Pages
3660-3670
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3207811858
Cited by
183
References
2
FWCI
13.45
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. https://app.cochat.ai/papers/10.1200/jco.21.01728
The paper
Wagner, A. J., Ravi, V., Riedel, R. F., Ganjoo, K., Van Tine, B. A., Chugh, R., Cranmer, L., Gordon, E. M., Hornick, J. L., Du, H., Grigorian, B., Schmid, A. N., Hou, S., Harris, K., Kwiatkowski, D. J., Desai, N. P., & Dickson, M. A. (2021). nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.01728

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.